What is HC Wainwright’s Forecast for Savara FY2024 Earnings?

Savara Inc (NASDAQ:SVRA) – Equities researchers at HC Wainwright increased their FY2024 EPS estimates for Savara in a research note issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($0.46) per share for the year, up from their previous forecast of ($0.48). HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for Savara’s Q4 2024 earnings at ($0.11) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at $0.00 EPS.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11).

A number of other analysts also recently issued reports on the company. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Savara in a report on Wednesday. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $10.17.

Savara Stock Performance

NASDAQ SVRA opened at $2.98 on Friday. The company has a market capitalization of $511.43 million, a PE ratio of -6.93 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 11.31 and a current ratio of 17.70. Savara has a 52-week low of $2.83 and a 52-week high of $5.70. The company has a 50-day simple moving average of $3.88 and a 200 day simple moving average of $4.19.

Hedge Funds Weigh In On Savara

Hedge funds and other institutional investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC lifted its position in Savara by 2.3% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock worth $72,536,000 after buying an additional 332,706 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Savara by 22.9% during the third quarter. Wellington Management Group LLP now owns 8,624,012 shares of the company’s stock worth $36,566,000 after acquiring an additional 1,608,522 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its holdings in shares of Savara by 103.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company’s stock worth $32,874,000 after acquiring an additional 4,157,385 shares during the last quarter. Vestal Point Capital LP boosted its stake in shares of Savara by 24.7% in the 3rd quarter. Vestal Point Capital LP now owns 8,090,000 shares of the company’s stock valued at $34,302,000 after purchasing an additional 1,600,000 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in shares of Savara by 17.5% during the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company’s stock valued at $28,547,000 after purchasing an additional 1,001,296 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.